Department of Cardiology, London Chest Hospital, Queen Mary University of London, Bonner Road, E2 9JX, London, UK.
Regen Med. 2011 Jul;6(4):525-33. doi: 10.2217/rme.11.29.
The field of autologous stem/progenitor cell therapy for cardiovascular diseases has moved rapidly from bench to bedside. In particular, a small number of pilot studies have demonstrated the safety and efficacy of this treatment in dilated cardiomyopathy (DCM), but this has to be validated in large randomized trials. Here we introduce the Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy (REGENERATE-DCM) trial, which to our knowledge, is the first randomized, double-blind, placebo-controlled trial worldwide to investigate the role of granulocyte-colony stimulating factor and autologous bone marrow-derived stem/progenitor cells to improve cardiac function in patients with DCM.
自体干细胞/祖细胞治疗心血管疾病的领域已经迅速从实验室走向临床。特别是，一些小规模的试验研究已经证明了这种治疗方法在扩张型心肌病（DCM）中的安全性和有效性，但这需要在大规模随机试验中得到验证。在这里，我们介绍骨髓源性成体干细胞治疗扩张型心肌病（REGENERATE-DCM）试验，据我们所知，这是全球首例旨在研究粒细胞集落刺激因子和自体骨髓源性干细胞/祖细胞在改善 DCM 患者心功能方面作用的随机、双盲、安慰剂对照试验。
